Here is the design of a clinical trial:

Official Title: Statin for Neuroprotection in Spontaneous Intracerebral Hemorrhage

Included conditions:
- Intracerebral Hemorrhage
- Statins

Study Armgroups:
- {'label': 'Statins group', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Statin']}
- {'label': 'Control group', 'type': 'NO_INTERVENTION'}

Interventions:
- {'type': 'DRUG', 'name': 'Statin', 'description': 'atorvastatin 20mg per day for 7 days', 'armGroupLabels': ['Statins group']}

Primary Outcomes:
- {'measure': 'Perihemorrhagic edema to hematoma ratio', 'timeFrame': '7 days'}

Please estimate the sample size based on the assumption: 
Significance level (Î±) is set at 0.05, power (1-Î²) is 90%, the test is two-sided, and the sample size ratio between the two groups is 1:1. A dropout rate of 20% or less is considered.
Sample size estimation
        Applying PASS software for sample size estimation, this study is a randomised controlled study of two independent samples mean comparison, set the test level Î±=0.05, test efficacy 1âÎ²=90%, Î² is two sided, the ratio of the sample size of the two groups is set as 1:1. Referring to the results of a clinical trial study published by our research group,17 the mean rPHE of ICH patients in the control group was 2.02 at 7âdays after enrolment, and the variance was 0.27. In this study, assuming that the mean rPHE in the statin treatment group decreased by about 10%, the PASS software estimated N1=39, N2=39 and N=78. As such, the minimum sample size was 78 patients. Considering a dropout rate of 20% or less, the overall sample size was estimated to be 98 cases.